Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment
Biologics in Therapy · 2012
DOI: 10.1007/s13554-012-0001-6 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biologics in Therapy, 2012. Verfasst von Andreas Reiff. Beteiligte Einrichtung: Division of Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
With the recent approval of tocilizumab as the first biologic for the treatment of systemic juvenile idiopathic arthritis (sJIA), an important unmet medical need for this historically challenging disease has now been met. The purpose of this review article is to revisit the established therapeutic options for sJIA, to summarize the history of the clinical trials with tocilizumab, and to discuss its role in the treatment of sJIA.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Rheumatology, Childrens Hospital Los Angeles, Los Angeles, CA USA.
Zitieren
APA
Reiff, A. (2012). Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment. Biologics in Therapy. https://doi.org/10.1007/s13554-012-0001-6
Vancouver
Reiff A. Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment. Biologics in Therapy. 2012. doi:10.1007/s13554-012-0001-6
BibTeX
@article{Reiff2012,
author = {Reiff, Andreas},
title = {Treatment of Systemic Juvenile Idiopathic Arthritis with Tocilizumab - the Role of Anti-Interleukin-6 Therapy After a Decade of Treatment},
journal = {Biologics in Therapy},
year = {2012},
doi = {10.1007/s13554-012-0001-6}
}
EUVIMED